BioVectra, a Charlottetown, Prince Edward Island, Canada-based contract development and manufacturing organization of intermediates and active pharmaceutical ingredients (APIs), has signed a long-term supply agreement with Keryx Biopharmaceuticals, a Boston, Massachusetts-headquartered biopharmaceutical company, to manufacture ferric citrate, API in Auryxia tablets, a medicine approved for treating two common complications of chronic kidney disease.

BioVectra has worked with Keryx to manufacture the ferric citrate API since 2003. BioVectra says it will prepare for anticipated growth in long-term ferric citrate API supply needs by expanding production capacity at its headquarters facility in a Charlottetown, Prince Edward Island, Canada.

Source: BioVectra